24 May 2013
Keywords: cv, therapeutics, amends, its, nda, ranexa, drugmaker
Article | 08 August 2005
US drugmaker CV Therapeutics has submitted an amendment to its New Drug Application for itrs drug candidate Ranexa (ranolazine) to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
23 May 2013
© 2013 thepharmaletter.com